IDHC vs. ABDX, GENI, VRCI, AGL, PRM, GDR, DMTR, LLAI, LLA, and DXRX
Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include Abingdon Health (ABDX), GENinCode (GENI), Verici Dx (VRCI), ANGLE (AGL), Proteome Sciences (PRM), genedrive (GDR), Deepmatter Group (DMTR), LungLife AI (LLAI), LLA.L,0P0001T9GN,0 (LLA), and Diaceutics (DXRX). These companies are all part of the "diagnostics & research" industry.
Integrated Diagnostics vs. Its Competitors
Abingdon Health (LON:ABDX) and Integrated Diagnostics (LON:IDHC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.
Integrated Diagnostics has a net margin of 17.21% compared to Abingdon Health's net margin of -20.72%. Integrated Diagnostics' return on equity of 30.45% beat Abingdon Health's return on equity.
In the previous week, Abingdon Health's average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.
6.1% of Abingdon Health shares are held by institutional investors. Comparatively, 40.2% of Integrated Diagnostics shares are held by institutional investors. 10.4% of Abingdon Health shares are held by company insiders. Comparatively, 28.0% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Integrated Diagnostics has higher revenue and earnings than Abingdon Health. Abingdon Health is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.
Abingdon Health has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Integrated Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.
Summary
Integrated Diagnostics beats Abingdon Health on 10 of the 11 factors compared between the two stocks.
Get Integrated Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Integrated Diagnostics Competitors List
Related Companies and Tools
This page (LON:IDHC) was last updated on 10/9/2025 by MarketBeat.com Staff
